Drug Trial Radar · NCT02908685
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
Last checked: Nov 19, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Oct 19, 2016
Primary completion
Sep 6, 2019
Study completion Oct 2, 2023
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of Risdiplam in adult and pediatric participants with Type 2 and Type 3 SMA. The study consists of two parts, an exploratory dose finding part (Part 1) of Risdiplam for 12 weeks and a confirmatory part (Part 2) of Risdiplam for 24 months.
Conditions
- Muscular Atrophy, Spinal
Interventions
PlaceboDrug
Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
RisdiplamDrug
Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Selected Part 2 Dose of Risdiplam for Participants With a Body Weight (BW) of >/=20kgTime frame: Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)
- Part 1: Selected Part 2 Dose of Risdiplam for Participants With BW of <20kgTime frame: Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)
- Part 2: Change From Baseline in the Total Motor Function Measure 32 (MFM-32) Total Score at Month 12Time frame: Baseline (Day-1) and Month 12
Locations
45 sites in 16 countries. Site status is shown where the registry gives one.
Stanford University Medical Center
Palo Alto, California
Columbia University Medical Center; The Neurological Institute of New York
New York, New York
UZ Gent
Ghent, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Chr de La Citadelle
Liège, Belgium
Instituto de Puericultura E Pediatria Martagão Gesteira
Rio de Janeiro, Rio de Janeiro, Brazil
Alberta Children's Hospital Division of Pediatric Neurology
Calgary, Alberta, Canada
London Health Sciences Centre; Children's Hospital; Pediatrics
London, Ontario, Canada
McGill University Health Centre - Glen Site
Montreal, Quebec, Canada
Peking University First Hospital
Beijing, China
Children's Hospital of Fudan University
Shanghai, China
Clinical Medical Center Zagreb; University Hospital Rebro Department of Paediatrics
Zagreb, Croatia
Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique ? L?ESCALE
Bron, France
Hopital Roger Salengro
Lille, France
CHU de Nantes - Hotel Dieu
Nantes, France
Hôpital Necker-Enfants Malades; Service de neuropédiatrie
Paris, France
Hopital Armand Trousseau
Paris, France
Universitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen
Freiburg im Breisgau, Germany
IRCCS Ospedale Pediatrico Bambino Gesù; U.O. Malattie Neuromuscolari e Neurodegenerative
Rome, Lazio, Italy
Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile
Rome, Lazio, Italy
IRCCS Istituto Giannina Gaslini; U.O.S.D. Centro di Miologia e Patologie Neurodegenerative
Genoa, Liguria, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Unità Operativa Complessa di Neurologia
Milan, Lombardy, Italy
Fondazione IRCCS Istituto Neurologico ?Carlo Besta?; UO di Neurologia dello Sviluppo
Milan, Lombardy, Italy
Fukuoka Children's Hospital
Fukuoka, Japan
Hiroshima University Hospital
Hiroshima, Japan
Hyogo Medical University Hospital
Hyōgo, Japan
Minami Kyushu National Hospital
Kagoshima, Japan
Miyagi Children's Hospital
Miyagi, Japan
Shiga Medical Center for Children
Shiga, Japan
Shizuoka Children's Hospital
Shizuoka, Japan
Jichi Medical University Hospital
Tochigi, Japan
Center Hospital of the National Center for Global Health and Medicine
Tokyo, Japan
National Center Of Neurology And Psychiatry Hospital
Tokyo, Japan
Szpital Gdanskiego Uniwersytetu Medycznego; Clinic of developmental neurology
Gda?sk, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu; Od. Kliniczny Neurologii Dzieci i M?odziezy
Późna, Poland
Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie
Warsaw, Poland
Russian Children Neuromuscular Center of Veltischev
Moscow, Moscow Oblast, Russia
Clinic for Neurology and Psychiatry for Children and Youth
Belgrade, Serbia
Hospital Universitari Vall d'Hebron; Servicio de Reumatologia
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.